Adjuvant T-DXd Cuts Recurrence Risk in Early Breast CancerAdjuvant T-DXd Cuts Recurrence Risk in Early Breast Cancer
(MedPage Today) — Adjuvant trastuzumab deruxtecan (T-DXd; Enhertu) significantly improved invasive disease-free survival compared with trastuzumab emtansine (T-DM1; Kadcyla) in high-risk HER2-positive early breast cancer, according to results…
STAT+: News you need to know about AI medical coding and GLP-1 microdosingSTAT+: News you need to know about AI medical coding and GLP-1 microdosing
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday. Telehealth companies Noom, Found, and Hims & Hers have all recently launched programs to prescribe “microdosed” GLP-1s. The companies say that in small doses Read More
New model forecasts 10-year heart risk after breast cancer treatmentNew model forecasts 10-year heart risk after breast cancer treatment
A multi-institution research team led by Georgetown University Medical Center has developed and validated a model estimating the 10-year risk of heart failure or cardiomyopathy after early-stage breast cancer treatment. Separating women into low, moderate, and high risk ranged from 1.7% in the lowest to 19.4% in the highest group.
STAT+: Pharmalittle: We’re reading about FDA disarray, microdosing GLP-1 weight loss drugs, and moreSTAT+: Pharmalittle: We’re reading about FDA disarray, microdosing GLP-1 weight loss drugs, and more
Rise and shine, everyone, another busy day is on the way. And it is getting off to a good start here on the Pharmalot campus, where we have cool breezes and clear blue skies greeting us today. Who could ask for anything more? Actually, we could — it is time to reheat the coffee kettle for Read More
Searching ‘weight’ can bring up Ozempic in results. It’s a drug advertising loopholeSearching ‘weight’ can bring up Ozempic in results. It’s a drug advertising loophole
There are strict rules about what drug companies can say in TV or print ads. But a new study shows there’s a lot more wiggle room when companies pay to sponsor online search results. There are strict rules about what drug companies can say in TV or print ads. But a new study shows Read More
STAT+: Microdosing aims to extend the lifespan of the GLP-1 compounding marketSTAT+: Microdosing aims to extend the lifespan of the GLP-1 compounding market
Noom, Found, and Hims & Hers have all launched programs to prescribe “microdosed” GLP-1s in the last three months, following in the footsteps of many smaller direct-to-consumer telehealth companies. Microdosing is getting a shot of promotion from Hollywood, too: Noom has promoted its program alongside a new celebrity spokesperson, actor Rebel Wilson, and TV host Read More
Bariatric Surgery May Cut Costs and Weight More Than GLP-1 DrugsBariatric Surgery May Cut Costs and Weight More Than GLP-1 Drugs
Despite growing prescription numbers and spending on glucagon-like peptide 1 (GLP-1) receptor agonists for obesity treatment, metabolic bariatric surgery may result in greater weight loss and lower costs, according to a recent study in JAMA Surgery. This comes as obesity experts have noticed decreased demand for the weight-loss surgery, which is often considered the “last Read More
Study shows semaglutide, tirzepatide and dulaglutide have similar gastrointestinal safety profiles in clinical settingsStudy shows semaglutide, tirzepatide and dulaglutide have similar gastrointestinal safety profiles in clinical settings
A new observational study compared the risk for severe gastrointestinal adverse events across dulaglutide, semaglutide, and tirzepatide in patients with type 2 diabetes (T2D). The study found that the medications have similar gastrointestinal safety profiles among those with T2D, providing clinicians with evidence to weigh the risks and benefits of these medications for their patients. Read More
GI Risks Similar Among GLP-1 Drugs, but Higher Than With SGLT-2 InhibitorsGI Risks Similar Among GLP-1 Drugs, but Higher Than With SGLT-2 Inhibitors
(MedPage Today) — Three popular GLP-1 receptor agonists carried similar risks for serious gastrointestinal (GI) events among adults with type 2 diabetes, although all higher than seen with sodium-glucose cotransporter 2 (SGLT-2) inhibitors, according… (MedPage Today) — Three popular GLP-1 receptor agonists carried similar risks for serious gastrointestinal (GI) events among adults with type Read More
STAT+: Novo Nordisk spent millions on weight loss searches that took people to its Ozempic website, analysis foundSTAT+: Novo Nordisk spent millions on weight loss searches that took people to its Ozempic website, analysis found
Over a recent two-year period, Novo Nordisk spent an estimated $7.5 million on more than 15,000 paid keywords related to weight loss searches and generated more than 2.4 million visits to Ozempic.com, even though the medicine is not approved to combat obesity, a new analysis found. Notably, more than 3,500 keywords contained no mention of Read More